BMO Capital analyst Gary Nachman notes Symphony data for January were released and show sales of Pacira Pharmaceuticals' Exparel of $23.2M, up a "healthy" 12.4% year-over-year. While the sales dropped 14.3% from December, January is normally lighter than December, Nachman tells investors in an intraday research note. Sales per selling day were below the levels for all Q4, the analyst notes, which he views as more concerning than the month-over-month decline. The analyst believes "some of the Exparel momentum" in Q4 "eased a bit" in January. He keeps a Market Perform rating on Pacira with a $32 price target.